Taiwan Opens New Center For Phase I, II Drug Trials
This article was originally published in PharmAsia News
Executive Summary
Taiwan has opened a university hospital center dedicated to conducting early-stage clinical trials of drugs, with an emphasis on cancer treatments. The National Health Research institutes and the National Cheng Kung University Hospital formed the project to conduct Phase I and Phase II trials. Taiwanese and foreign pharmaceutical companies together already have commissioned the center to conduct trials on about 40 cancer drugs they want to test, about one-fifth of them from local firms. (Click here for more
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.